BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Uncovering this genetic driver of CML lead to the development of a selective inhibitor of BCR-ABL, imatinib, which exhibited broader treatment coverage because, unlike other gene mutations, the Bcr-Abl gene fusion occurs in almost all CML patients.